[P-800(1T14e-11)] The SGLT2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model

^○Naoki Yoshioka^1,2, Miyako Tanaka¹, Kozue Ochi¹, Akiko Watanabe¹, Michiko Itoh^3,4, Masatoshi Ishigami², Mitsuhiro Fujishiro², Takayoshi Suganami¹ (1.Department of Molecular Medicine and Metabolism, Research Institute of Environmental Medicine, Nagoya University, 2.Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, 3.Kanagawa Institute of Industrial Science and Technology, 4.Department of Metabolic Syndrome and Nutritional Science, Research Institute of Environmental Medicine, Nagoya University)

キーテクノロジー：疾患動物モデル

肝がん、非アルコール性脂肪肝炎、肥満、糖尿病、SGLT2阻害薬